Enlaza is developing first-in-class covalent protein therapeutics to transform the treatment of cancer and other serious diseases
Enlaza is developing first-in-class covalent protein therapeutics to transform the treatment of cancer and other serious diseases. Their proprietary War-Lock technology enables the generation of unique, highly-selective biologic drugs that irreversibly lock to disease-related targets, improving efficacy and safety profiles.